Skip to main content
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, ti

Dr. John Cush RheumNow

1 year 1 month ago
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/5VrE4OpZ4N
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns

Pregnancy in patients with systemic lupus erythematosus (SLE) c

Dr. John Cush RheumNow

1 year 1 month ago
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns Pregnancy in patients with systemic lupus erythematosus (SLE) continues to carry significantly elevated risks, with maternal mortality rates nearly five times higher than in the general population. https://t.co/3G7Eftt0Kg https://t.co/X3SUl6FTHO
TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in

Dr. John Cush RheumNow

1 year 1 month ago
TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/XNd8uYLQsJ
Upcoming Lupus Nephritis Pipeline

1. Gazyva (obinutuzumab) – due for FDA/EMA decision

2. Saphnelo IV (anifrolumab) ?

Dr. John Cush RheumNow

1 year 1 month ago
Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN 3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/jEv2uvhkqK
FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for

Dr. John Cush RheumNow

1 year 1 month ago
FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for SLE and active LN. BEL SC dosing for Pediatric SLE: 200 mg qwk (>40 kg) or 200 mg EOW (q2wk) if 15-40 kg. https://t.co/zrskHdw9Jx https://t.co/jkqygmfJPv
MRI Lesions in Early axSpA vs Non-axSpA

Dr. Adela Castro reports on abstract OP0310 presented at the 2025 EULAR meetin

Dr. John Cush RheumNow

1 year 1 month ago
MRI Lesions in Early axSpA vs Non-axSpA Dr. Adela Castro reports on abstract OP0310 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/sVWpyUT1IY https://t.co/wzobROoH1K
Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.
ICYMI: Proinflammatory Diet Increases Gout Risk
  • MedPage Today
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated. Data from the two iterations of the Nurses' Health Study, in which more than 170,000 women were followed for more than two decades, indicated that diets scoring high on the Empirical Dietary Inflammatory Pattern (EDIP) index nearly doubled the risk for new-onset gout after adjusting for body mass index.
RA: Using AI for Reading PET/CT
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data,
Lessons on Uveitis and AxSpA
JAK Inhibitors: The Latest from the JAK-pot Study

Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kina

Dr. John Cush RheumNow

1 year 1 month ago
JAK Inhibitors: The Latest from the JAK-pot Study Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory https://t.co/KiOZuphQTx
Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyo

Dr. John Cush RheumNow

1 year 1 month ago
Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyopathic form with distinctive skin findings & rapidly progressive interstitial lung dz. Rx includes Hi dose steroids, calcineurin inhib & IV CTX (maybe JAKi, MMF)
×